EE04090B1 - 7-(2-oksa-5,8-diasabitsüklo[4.3.0]non-8-üül) kinoloonkarboksüülhappe ja -naftüridoonkarboksüülhappederivaadid kasutamiseks Helicobacter pylori infektsioonide ja nendega kaasnevate gastroduodenaalsetehaiguste raviks - Google Patents

7-(2-oksa-5,8-diasabitsüklo[4.3.0]non-8-üül) kinoloonkarboksüülhappe ja -naftüridoonkarboksüülhappederivaadid kasutamiseks Helicobacter pylori infektsioonide ja nendega kaasnevate gastroduodenaalsetehaiguste raviks

Info

Publication number
EE04090B1
EE04090B1 EEP199900248A EE9900248A EE04090B1 EE 04090 B1 EE04090 B1 EE 04090B1 EE P199900248 A EEP199900248 A EE P199900248A EE 9900248 A EE9900248 A EE 9900248A EE 04090 B1 EE04090 B1 EE 04090B1
Authority
EE
Estonia
Prior art keywords
carboxylic acid
oxa
diazabicyclo
helicobacter pylori
treatment
Prior art date
Application number
EEP199900248A
Other languages
English (en)
Estonian (et)
Other versions
EE9900248A (et
Inventor
Matzke Michael
Petersen Uwe
Jaetsch Thomas
Bartel Stephan
Schenke Thomas
Himmler Thomas
Baasner Bernd
Werling Hans-Otto
Schaller Klaus
Labischinski Harald
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of EE9900248A publication Critical patent/EE9900248A/xx
Publication of EE04090B1 publication Critical patent/EE04090B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EEP199900248A 1996-12-16 1997-12-04 7-(2-oksa-5,8-diasabitsüklo[4.3.0]non-8-üül) kinoloonkarboksüülhappe ja -naftüridoonkarboksüülhappederivaadid kasutamiseks Helicobacter pylori infektsioonide ja nendega kaasnevate gastroduodenaalsetehaiguste raviks EE04090B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19652239A DE19652239A1 (de) 1996-12-16 1996-12-16 Verwendung von 7-(2-Oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-chinolon- und -naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen
PCT/EP1997/006781 WO1998026779A1 (de) 1996-12-16 1997-12-04 Verwendung von 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-chinoloncarbonsäure- und -naphthyridoncarbonsäure-derivaten zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen

Publications (2)

Publication Number Publication Date
EE9900248A EE9900248A (et) 1999-12-15
EE04090B1 true EE04090B1 (et) 2003-08-15

Family

ID=7814837

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900248A EE04090B1 (et) 1996-12-16 1997-12-04 7-(2-oksa-5,8-diasabitsüklo[4.3.0]non-8-üül) kinoloonkarboksüülhappe ja -naftüridoonkarboksüülhappederivaadid kasutamiseks Helicobacter pylori infektsioonide ja nendega kaasnevate gastroduodenaalsetehaiguste raviks

Country Status (27)

Country Link
US (2) US6133260A (cs)
EP (1) EP0946176B1 (cs)
JP (3) JP3463939B2 (cs)
KR (1) KR100536153B1 (cs)
CN (1) CN100335054C (cs)
AT (1) ATE214929T1 (cs)
AU (1) AU717751B2 (cs)
BG (1) BG64615B1 (cs)
BR (1) BR9714032A (cs)
CA (1) CA2274894C (cs)
CZ (2) CZ297363B6 (cs)
DE (2) DE19652239A1 (cs)
DK (1) DK0946176T3 (cs)
EA (1) EA002477B1 (cs)
EE (1) EE04090B1 (cs)
ES (1) ES2175519T3 (cs)
HU (1) HU226523B1 (cs)
IL (1) IL130311A (cs)
NO (1) NO325617B1 (cs)
NZ (2) NZ336228A (cs)
PL (1) PL191193B1 (cs)
PT (1) PT946176E (cs)
RS (1) RS49684B (cs)
SK (2) SK283224B6 (cs)
TR (1) TR199901754T2 (cs)
UA (1) UA57055C2 (cs)
WO (1) WO1998026779A1 (cs)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19633805A1 (de) * 1996-02-23 1997-08-28 Bayer Ag Gegenenenfalls substituierte 8-Cyan-l-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäuren und ihre Derivate
ES2203254T3 (es) * 1998-11-18 2004-04-01 Asahi Glass Company Ltd. Derivados de acido aminoacrilico y procedimiento de produccion correspondiente.
DE19917617A1 (de) * 1999-04-19 2000-10-26 Bayer Ag -(-)Enantiomeres des 2-[2-(1-Chlor-cyclopropyl)-3-(2-chlorphenyl) 2-hydroxy-propyl]-2,4-dihydro-[1,2,4]-triazol-3-thions
CA2376760C (en) * 1999-07-01 2008-11-25 Wakunaga Pharmaceutical Co., Ltd. Quinolinecarboxylic acid derivative or salts thereof
UY26380A1 (es) * 1999-10-08 2001-04-30 Smithkline Beecham Corp Inhibidores de fab i
ES2320984T3 (es) * 2001-04-06 2009-06-01 Affinium Pharmaceuticals, Inc. Inhibidores de fab i.
JP4859460B2 (ja) * 2002-12-06 2012-01-25 アフィニウム ファーマシューティカルズ, インク. ヘテロ環化合物、その製造方法および治療におけるその使用
CA2519429C (en) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
EP1669354B1 (en) 2003-09-29 2013-03-20 Daiichi Sankyo Company, Limited 8-cyanoquinolonecarboxylic acid derivative
US7759362B2 (en) 2004-04-21 2010-07-20 Institut Of Medicinal Biotechnology Chinese Academy Of Medical Sciences Quinolonecarboxylic acid compounds, preparation methods and pharmaceutical uses thereof
CN1244582C (zh) * 2004-04-21 2006-03-08 中国医学科学院医药生物技术研究所 喹诺酮羧酸类化合物及其制备方法和医药用途
CA2568914C (en) 2004-06-04 2013-09-24 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
WO2007067416A2 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
US8318720B2 (en) * 2006-07-20 2012-11-27 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as Fab I inhibitors
EP3255045A1 (en) 2007-02-16 2017-12-13 Debiopharm International SA Salts, prodrugs and polymorphs of fab i inhibitors
MX2012000136A (es) * 2009-07-02 2012-02-08 Alcon Res Ltd Composiciones que comprenden finafloxacina y metodos para tratar infecciones oftalmicas, oticas, o nasales.
RU2449805C1 (ru) 2011-01-27 2012-05-10 Общество С Ограниченной Ответственностью "Гармония" Пептидная фармацевтическая композиция, средство на ее основе для лечения гастродуоденальных заболеваний, вызываемых helicobacter pylori, и способ его использования
JP6085026B2 (ja) 2012-06-19 2017-02-22 デビオファーム インターナショナル エスエーDebiopharm International Sa (e)−n−メチル−n−((3−メチルベンゾフラン−2−イル)メチル)−3−(7−オキソ−5,6,7,8−テトラヒドロ−1,8−ナフチリジン−3−イル)アクリルアミドのプロドラッグ誘導体
US9504691B2 (en) * 2012-12-06 2016-11-29 Alcon Research, Ltd. Finafloxacin suspension compositions
US20150045739A1 (en) 2013-08-12 2015-02-12 Novartis Ag Method for treating otic infections after tympanostomy tube placement
DE102014115951A1 (de) 2014-11-03 2016-05-04 Merlion Pharmaceuticals Pte Ltd. Zusammensetzungen, die Finafloxacin und Tris enthalten
DE102015100068A1 (de) 2015-01-06 2016-07-07 Merlion Pharmaceuticals Pte Ltd. Finafloxacin zur verwendung bei der behandlung von harnwegsinfektionen
EP3419628B1 (en) 2016-02-26 2020-10-14 Debiopharm International SA Medicament for treatment of diabetic foot infections
CN107987074B (zh) * 2017-10-27 2020-12-29 浙江美诺华药物化学有限公司 一种普拉沙星的合成方法
PE20201257A1 (es) 2018-04-25 2020-11-16 Bayer Animal Health Gmbh Proceso para la hidrolisis de esteres carboxilicos de quinolona
WO2020165407A1 (en) 2019-02-14 2020-08-20 Debiopharm International S.A. Afabicin formulation, method for making the same
JP7418475B2 (ja) 2019-06-14 2024-01-19 デバイオファーム インターナショナル エス.エー. バイオフィルムが関与する細菌感染症を治療するための医薬及びその使用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822801A (en) * 1984-07-20 1989-04-18 Warner-Lambert Company 4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivative as antibacterial agents
JPS62205060A (ja) * 1986-03-04 1987-09-09 Kyorin Pharmaceut Co Ltd 8位置換キノロンカルボン酸誘導体
DE3702393A1 (de) * 1987-01-28 1988-08-11 Bayer Ag 8-cyano-1-cyclopropyl-1,4-dihydro-4-oxo- 3-chinolincarbonsaeuren, verfahren zu ihrer herstellung und diese enthaltende antibakterielle mittel
US5563138A (en) * 1987-04-16 1996-10-08 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
US4889857A (en) * 1987-10-12 1989-12-26 Yoshitomi Pharmaceutical Industries, Ltd. Quinolonecarboxylic acid compounds and pharmaceutical use thereof
WO1989005643A1 (en) * 1987-12-18 1989-06-29 Pfizer Inc. Heterocyclic-substituted quinoline-carboxylic acids
JP2844079B2 (ja) * 1988-05-23 1999-01-06 塩野義製薬株式会社 ピリドンカルボン酸系抗菌剤
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
US5147873A (en) * 1988-08-23 1992-09-15 Pfizer Inc. Amino-substituted bridged azabicyclic quinolone carboxylic acids and esters
CA2001203C (en) * 1988-10-24 2001-02-13 Thomas P. Demuth, Jr. Novel antimicrobial dithiocarbamoyl quinolones
US5262417A (en) * 1988-12-06 1993-11-16 The Upjohn Company Antibacterial quinolone compounds
US5407932A (en) * 1989-03-31 1995-04-18 Wakunaga Seiyaku Kabushiki Kaisha Quinolone derivatives and antibacterial agents containing the same
US5252734A (en) * 1989-04-03 1993-10-12 Bayer Aktiengesellschaft Antibacterial 5-alkylquinolonecarboxylic acids
US5140033A (en) * 1989-04-03 1992-08-18 Bayer Aktiengesellschaft Antibacterial 5-alkylquinolonecarboxylic acids
DE3910663A1 (de) * 1989-04-03 1990-10-04 Bayer Ag 5-alkylchinoloncarbonsaeuren
US5164402A (en) * 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids
KR910009330B1 (ko) * 1989-10-23 1991-11-11 재단법인 한국화학연구소 항균작용을 갖는 퀴놀린계 화합물과 그의 제조방법
DE4200415A1 (de) 1992-01-10 1993-07-15 Bayer Ag Enantiomerenreine 2-oxa-5,8-diazabicyclo(4.3.0)nonane sowie verfahren zu ihrer herstellung
TW209865B (cs) * 1992-01-10 1993-07-21 Bayer Ag
NO301165B1 (no) * 1992-12-25 1997-09-22 Daiichi Seiyaku Co Bicykliske aminderivater og antibakterielle midler inneholdende disse
DE4309964A1 (de) 1993-03-26 1994-09-29 Bayer Ag Verfahren zur Herstellung enantiomerenreiner trans-2-Oxa-5,8-diazabicyclo[4.3.0]nonane
AU4272793A (en) * 1993-04-24 1994-11-21 Korea Research Institute Of Chemical Technology Novel quinolone carboxylic acid derivatives and process for preparing the same
US5532239A (en) * 1993-08-02 1996-07-02 Assistance Publique - Hopitaux De Paris Therapeutic application of fluoroquinolone derivatives
DE4329600A1 (de) * 1993-09-02 1995-03-09 Bayer Ag Pyrido [1,2,3-d,e] [1,3,4] benzoxadiazinderivate
EP0676199B1 (en) * 1994-04-07 1998-09-02 Pfizer Inc. Use of trovafloxacin or derivatives thereof for the manufacture of a medicament for the treatment of H. pylori infections
GB2289674A (en) * 1994-05-23 1995-11-29 Pfizer Antibacterial naphthyridine
JPH0848629A (ja) * 1994-08-08 1996-02-20 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸誘導体およびそれを有効成分とする抗ピロリ菌剤

Also Published As

Publication number Publication date
AU5854198A (en) 1998-07-15
CZ216899A3 (cs) 2000-02-16
HU226523B1 (en) 2009-03-30
NO992903D0 (no) 1999-06-14
JP2000514825A (ja) 2000-11-07
UA57055C2 (uk) 2003-06-16
PL191193B1 (pl) 2006-03-31
CA2274894A1 (en) 1998-06-25
CN100335054C (zh) 2007-09-05
HUP0000450A2 (hu) 2000-10-28
KR20000069483A (ko) 2000-11-25
BR9714032A (pt) 2000-05-09
DE19652239A1 (de) 1998-06-18
SK14962000A3 (sk) 2003-01-09
ES2175519T3 (es) 2002-11-16
YU27499A (sh) 2002-10-18
EA002477B1 (ru) 2002-06-27
SK79599A3 (en) 2001-01-18
JP2009235106A (ja) 2009-10-15
BG64615B1 (bg) 2005-09-30
IL130311A0 (en) 2000-06-01
DE59706808D1 (de) 2002-05-02
CZ297363B6 (cs) 2006-11-15
SK283224B6 (sk) 2003-03-04
NZ336228A (en) 2000-12-22
EA199900526A1 (ru) 2000-08-28
CA2274894C (en) 2009-04-07
EE9900248A (et) 1999-12-15
JP5112395B2 (ja) 2013-01-09
JP4463380B2 (ja) 2010-05-19
NO992903L (no) 1999-06-14
PT946176E (pt) 2002-08-30
US6133260A (en) 2000-10-17
HUP0000450A3 (en) 2001-02-28
SK283223B6 (sk) 2003-03-04
AU717751B2 (en) 2000-03-30
EP0946176A1 (de) 1999-10-06
IL130311A (en) 2004-01-04
JP3463939B2 (ja) 2003-11-05
NO325617B1 (no) 2008-06-30
US6432948B1 (en) 2002-08-13
HK1025517A1 (zh) 2000-11-17
NZ506162A (en) 2001-06-29
DK0946176T3 (da) 2002-06-10
ATE214929T1 (de) 2002-04-15
KR100536153B1 (ko) 2005-12-14
CN1245428A (zh) 2000-02-23
BG103474A (en) 2000-01-31
RS49684B (sr) 2007-11-15
PL333928A1 (en) 2000-01-31
JP2000351781A (ja) 2000-12-19
WO1998026779A1 (de) 1998-06-25
TR199901754T2 (xx) 1999-09-21
EP0946176B1 (de) 2002-03-27
CZ297364B6 (cs) 2006-11-15

Similar Documents

Publication Publication Date Title
EE04090B1 (et) 7-(2-oksa-5,8-diasabitsüklo[4.3.0]non-8-üül) kinoloonkarboksüülhappe ja -naftüridoonkarboksüülhappederivaadid kasutamiseks Helicobacter pylori infektsioonide ja nendega kaasnevate gastroduodenaalsetehaiguste raviks
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
AU2003240680A8 (en) 1h-imidazo(4,5-c) quinoline derivatives in the treatment of protein kinase dependent diseases
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
MA27566A1 (fr) Inhibiteurs de 4-oxo-1-(3-phenyle substitue -1, 4-dihydro-1, 8-naphthyridine-3-carboxamide phosphodiesterase-4
FI873248A0 (fi) 7-((3-(aminometyl)-3-alkyl)-1 -pyrrolidinyl)-kinolin-karboxylsyror.
EE03526B1 (et) Leukotrieen-antagonistliku toimega bensopüraanderivaadid, nende valmistamismeetod ja kasutamine
PL328123A1 (en) Derivatives of banzo[c]quinolysine and method of obtaining them
ATE229336T1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
DK0704443T3 (da) Quinolon- og naphthyridoncarboxylsyrederivater
BR0014052A (pt) Derivados de aminas
DE69924105D1 (de) Iga produktionsinhibitoren
ES542583A0 (es) Procedimiento para la preparacion de nuevos derivados de triazolopirimidina.

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231